×
Pharming Group Pre-Tax Profit Margin 2013-2024 | PHGUF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Pharming Group pre-tax profit margin from 2013 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
View More
Pharming Group Pre-Tax Profit Margin 2013-2024 | PHGUF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Pharming Group pre-tax profit margin from 2013 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$142.2B
Bristol Myers Squibb (BMY)
$117.1B
Gilead Sciences (GILD)
$117.1B
Vertex Pharmaceuticals (VRTX)
$105.1B
CSL (CSLLY)
$85.9B
Regeneron Pharmaceuticals (REGN)
$78.5B
GSK (GSK)
$70.5B
Argenex SE (ARGX)
$38B
Alnylam Pharmaceuticals (ALNY)
$31.4B
BioNTech SE (BNTX)
$27.4B
Biogen (BIIB)
$21.7B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$17.7B
Moderna (MRNA)
$15.5B
Genmab (GMAB)
$13.5B
Incyte (INCY)
$13.5B
BioMarin Pharmaceutical (BMRN)
$12.7B
Insmed (INSM)
$12.6B
Sarepta Therapeutics (SRPT)
$11.6B
Bio-Techne Corp (TECH)
$11.6B
Exact Sciences (EXAS)
$10.8B
Vaxcyte (PCVX)
$10.7B
QIAGEN (QGEN)
$10.3B
Swedish Orphan Biovitrum (BIOVF)
$9.8B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$9B
Roivant Sciences (ROIV)
$8.7B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8.2B